UnitedHealth Unit, CNSide Diagnostics Secure National Coverage for Tumor Cell Lab Test

UnitedHealth Group Inc. has signed a national coverage deal with CNSide Diagnostics for their tumor cell lab test. The deal aims to provide coverage for the test across the country, increasing access to this diagnostic tool for patients. UnitedHealth Group is a leading supplier of healthcare products and services, with income from health insurance, prescription insurance plan management services, and computer services.

UnitedHealth Group Inc. (NYSE: UNH) has signed a national coverage agreement with CNSide Diagnostics, a subsidiary of Plus Therapeutics Inc. (NASDAQ: PSTV), to provide access to the CNSide Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT) across the United States. The agreement, effective September 15, 2025, will cover over 51 million people Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit^[1].

The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The test has demonstrated 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer^[2]. Since 2020, more than 11,000 tests have been performed at over 120 U.S. cancer institutions, showcasing the test's clinical utility and market validation Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer^[2].

The agreement with UnitedHealthcare, a unit of UnitedHealth Group, marks a significant step in expanding access to this critical diagnostic tool. UnitedHealth Group is a leading supplier of healthcare products and services, with revenue generated from health insurance, prescription insurance plan management services, and computer services Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer^[2].

CNSide Diagnostics recently received a certificate of accreditation from CMS for its lab located in Houston, Texas, ensuring compliance with Clinical Laboratory Improvement Amendments regulations Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit^[1]. Additionally, Plus Therapeutics received an advance payment of $1.9 million from the Cancer Prevention and Research Institute of Texas (CPRIT) Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit^[1].

The stock of Plus Therapeutics was down 2.03% at $0.39 during premarket trading on Thursday, trading near its 52-week low of $0.16 Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit^[1]. The company's focus on developing targeted radiotherapeutics for difficult-to-treat cancers positions it as a key player in the healthcare innovation sector.